Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

BS B2B Bureau  |  Basel, Switzerland 

Johnson & Johnson in talks to acquire Actelion

& (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015.

Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, has its corporate headquarters in Basel, Switzerland.

RECOMMENDED FOR YOU

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015
& (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015.

Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, has its corporate headquarters in Basel, Switzerland.
image
Business Standard
177 22

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

& (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015.

Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, has its corporate headquarters in Basel, Switzerland.

image
Business Standard
177 22